The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers
Abstract
Ovarian malignancies are a leading cause of cancer-related death for US women. High-grade serous ovarian carcinomas (HGSOCs), the most common ovarian cancer subtype, are aggressive tumors with poor outcomes. Mutations in TP53 are common in HGSOCs, with a subset resulting in p53 aggregation and misregulation. ReACp53 is a peptide designed to inhibit mutant p53 aggregation and has been shown efficacious in targeting cancer cells in vitro and in vivo. As p53 regulates apoptosis, combining ReACp53 with carboplatin represents a logical therapeutic strategy. The efficacy of this combinatorial approach was tested in eight ovarian cancer cell lines and 10 patient HGSOC samples using an in vitro organoid drug assay, with the SynergyFinder tool utilized for calculating drug interactions. Results demonstrate that the addition of ReACp53 to carboplatin enhanced tumor cell targeting in the majority of samples tested, with synergistic effects measured in 2 samples, additivity measured in 14 samples, and antagonism measured in 1 sample. This combination was found to be synergistic in OVCAR3 ovarian cancer cells in vitro through enhanced apoptosis, and survival of mice bearing OVCAR3 intraperitoneal xenografts was extended when treated with the addition of ReACp53 to carboplatin versus carboplatin alone. Results suggest that carboplatin and ReACp53 may be a potential strategy in targeting a subset of HGSOCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ReACp53 also inhibits the growth of various tumors characterized by p53 mutations.490,492–494”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [493]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
Yadav, B., Wennerberg, K., Aittokallio, T., & Tang, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.09.001 · Cited by 845
Perets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.013 · Cited by 596
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403 · cited 2×
“OVCAR3 cells are known to be platinum-sensitive [26]; therefore, in these experiments, tumor-bearing mice were treated with carboplatin at a dose of 10 mg/kg IP 1×/week.”
BackgroundMethodPhan, N., Hong, J. J., Tofig, B., Mapua, M., Elashoff, D., Moatamed, N. A., Huang, J., Memarzadeh, S., Damoiseaux, R., & Soragni, A. (2019) · Communications Biology · doi:10.1038/s42003-019-0305-x · Cited by 269 · cited 5×
“The specificity of the peptide was tested in vitro using three cell lines (OVCAR3, SKOV3, and MCF7) using a previously reported high throughput in vitro organoid drug assay (Supplementary Figure S1C) [19,20].”
MethodInfluentialSelf-citation
Research works printed but not linked: 27
- Siegel, 2021, Cancer Statistics, 2021, CA Cancer J. Clin., 71, 7, 10.3322/caac.21654 · DOI · Paper page
- Kurman, 2008, Pathogenesis of Ovarian Cancer: Lessons from Morphology and Molecular Biology and Their Clinical Implications, Int. J. Gynecol. Pathol., 27, 151
- Berek, 2018, Cancer of the Ovary, Fallopian Tube, and Peritoneum, Int. J. Gynecol. Obstet., 143, 59, 10.1002/ijgo.12614 · DOI · Paper page
- Armstrong, 2019, NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019, J. Natl. Compr. Cancer Netw., 17, 896, 10.6004/jnccn.2019.0039 · DOI · Paper page
- (2011). Cancer Genome Atlas Research Network Integrated Genomic Analyses of Ovarian Carcinoma. Nature, 474, 609–615. · DOI · Paper page
- Gerstung, 2020, The Evolutionary History of 2658 Cancers, Nature, 578, 122, 10.1038/s41586-019-1907-7 · DOI · Paper page
- Lee, 2007, A Candidate Precursor to Serous Carcinoma That Originates in the Distal Fallopian Tube, J. Pathol., 211, 26, 10.1002/path.2091 · DOI · Paper page
- Kindelberger, 2007, Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship, Am. J. Surg. Pathol., 31, 161, 10.1097/01.pas.0000213335.40358.47 · DOI · Paper page
- Lane, 1992, P53, Guardian of the Genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
- Hientz, 2017, The Role of P53 in Cancer Drug Resistance and Targeted Chemotherapy, Oncotarget, 8, 8921, 10.18632/oncotarget.13475 · DOI · Paper page
- Robles, 2010, Clinical Outcomes and Correlates of TP53 Mutations and Cancer, Cold Spring Harb. Perspect. Biol., 2, a001016, 10.1101/cshperspect.a001016 · DOI · Paper page
- Zhang, 2020, Therapeutic Potential of ReACp53 Targeting Mutant P53 Protein in CRPC, Prostate Cancer Prostatic Dis., 23, 160, 10.1038/s41391-019-0172-z · DOI · Paper page
- Palanikumar, 2021, Protein Mimetic Amyloid Inhibitor Potently Abrogates Cancer-Associated Mutant P53 Aggregation and Restores Tumor Suppressor Function, Nat. Commun, 12, 3962, 10.1038/s41467-021-23985-1 · DOI · Paper page
- Lei, 2021, Molecular Dynamics Study on the Inhibition Mechanisms of ReACp53 Peptide for P53–R175H Mutant Aggregation, Phys. Chem. Chem. Phys., 23, 23032, 10.1039/D1CP03094A · DOI · Paper page
- Wang, 2017, Multisite Aggregation of P53 and Implications for Drug Rescue, Proc. Natl. Acad. Sci. USA, 114, E2634
- Kanapathipillai, M. (2018). Treating P53 Mutant Aggregation-Associated Cancer. Cancers, 10. · DOI · Paper page
- Nguyen, H.T.L., and Soragni, A. (2020). Patient-Derived Tumor Organoid Rings for Histologic Characterization and High-Throughput Screening. STAR Protoc., 100056. · DOI · Paper page
- van der Auwera, G.A., and Brian, D. (2020). O’Connor Genomics in the Cloud: Using docker, GATK, and WDL in Terra (1st Edition), O’Rielly Media, Inc.
- Bouaoun, 2016, TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data, Hum. Mutat., 37, 865, 10.1002/humu.23035 · DOI · Paper page
- Ianevski, 2020, SynergyFinder 2.0: Visual Analytics of Multi-Drug Combination Synergies, Nucleic Acids Res., 48, W488, 10.1093/nar/gkaa216 · DOI · Paper page
- Marqus, 2017, Evaluation of the Use of Therapeutic Peptides for Cancer Treatment, J. Biomed. Sci., 24, 21, 10.1186/s12929-017-0328-x · DOI · Paper page
- Haley, 2016, Functional Characterization of a Panel of High-Grade Serous Ovarian Cancer Cell Lines as Representative Experimental Models of the Disease, Oncotarget, 7, 32810, 10.18632/oncotarget.9053 · DOI
- Siddik, 2003, Cisplatin: Mode of Cytotoxic Action and Molecular Basis of Resistance, Oncogene, 22, 7265, 10.1038/sj.onc.1206933 · DOI · Paper page
- Robinson, 2015, Integrative Clinical Genomics of Advanced Prostate Cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 · DOI · Paper page
- Zhang, 2017, Proteomic Identification of ERP29 as a Key Chemoresistant Factor Activated by the Aggregating P53 Mutant Arg282Trp, Oncogene, 36, 5473, 10.1038/onc.2017.152 · DOI
- Zeng, 2016, Targeting Aggregation of Wilde-Type P53 and Mutant P53 with ReACp53 As a Novel Therapeutic Concept for AML, Blood, 128, 3944, 10.1182/blood.V128.22.3944.3944 · DOI
- Patra, 2018, Nano Based Drug Delivery Systems: Recent Developments and Future Prospects, J. Nanobiotechnol., 16, 71, 10.1186/s12951-018-0392-8 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Metadata
- Authors
- Neal, A., Lai, T., Singh, T., Rahseparian, N., Grogan, T., Elashoff, D., Scott, P., Pellegrini, M., & Memarzadeh, S.
- Affiliations
- Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
- Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
- Department of Life, Earth, and Environmental Sciences, West Texas A&M University, Canyon, TX 79016, USA
- UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, CA 90095, USA
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-11-24
- Volume
- 13
- Issue
- 23
- Pages
- 5908
- ISSN
- 2072-6694
- Cited by
- 17
- References
- 5
- Language
- en
- Funders
- American Cancer Society (RSG-14-217-01-TBG)
- Department of Veterans Affairs (I01BX004651)
- National Institutes of Health (U54-CA-143931)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers. https://app.cochat.ai/papers/10.3390/cancers13235908
- The paper
- Neal, A., Lai, T., Singh, T., Rahseparian, N., Grogan, T., Elashoff, D., Scott, P., Pellegrini, M., & Memarzadeh, S. (2021). Combining ReACp53 with Carboplatin to Target High-Grade Serous Ovarian Cancers. Cancers. https://doi.org/10.3390/cancers13235908
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.